Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab

Sridhar Chilimuri, Nikhitha Mantri, Sudharsan Gongati, Maleeha Zahid, Haozhe Sun

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.

Original languageEnglish
Article number219
Pages (from-to)1-3
Number of pages3
Issue number3
StatePublished - 2021


  • B-Cell
  • COVID-19
  • Humoral immunity
  • Multiple sclerosis
  • Ocrelizumab
  • Vaccination


Dive into the research topics of 'Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab'. Together they form a unique fingerprint.

Cite this